Skip to main content

Table 2 Primary endpoint for efficacy

From: Effects of adding a neurokinin-1 receptor antagonist to 5 mg olanzapine, a 5-hydroxytryptamine-3 receptor antagonist, and dexamethasone for preventing carboplatin-induced nausea and vomiting: a propensity score-matched analysis

Outcome

Non-NK1RA group

NK1RA group

Risk Difference

P value

(n = 31)

(n = 31)

(95% CI)

CR

 Overall

29 (93.5%)

30 (96.8%)

-3.2% (-18.7 to 10.9)

1.000

 Acute

31 (100%)

31 (100%)

0%

 

 Delayed

29 (93.5%)

30 (96.8%)

-3.2% (-18.7 to 10.9)

1.000

CC

 Overall

29 (93.5%)

29 (93.5%)

0% (-16.6 to 16.6)

1.000

 Acute

31 (100%)

31 (100%)

0%

 

 Delayed

29 (93.5%)

29 (93.5%)

0% (-16.6 to 16.6)

1.000

TC

 Overall

27 (87.1%)

26 (83.9%)

3.2% (-16.6 to 22.9)

1.000

 Acute

31 (100%)

30 (96.8%)

3.2% (-8.4 to 16.7)

1.000

 Delayed

27 (87.1%)

27 (87.1%)

0% (-19.0 to 19.0)

1.000

  1. CR Complete response, CC Complete control, TC Total control, CI Confidence interval